Athletes abuse recombinant human growth hormone (rhGH) in an attempt to lose
body fat and build muscle mass. However, extensive clinical studies have
demonstrated that even doses of rhGH, which promote large increases in reported
“lean body mass” do not translate into increased myofibrillar strength. Most of this
increased lean mass is due to water retention and collagen synthesis. Furthermore,
the long-term clinical management of both intentional and severe supratherapeutic
abuse of hGH has taught us that the negative health consequences of chronic use
include marked insulin resistance and acromegalic cardiomyopathy. From an antidoping
perspective, it represents one of the most formidable analytical challenges.
Since exogenous hGH is biologically and immunochemically identical to the
endogenous hormone, this structural parity severely complicates detection for the
World Anti-Doping Agency (WADA). Ongoing scientific research has led to the
development of isoform and biomarker-based tests to detect abuse of hGH by
athletes. To continue to protect the health and safety of athletes and to promote
integrity in competitive sports, WADA and allied anti-doping authorities must
continuously advance hGH detection methodologies to combat ongoing abuse. This
Volume summarizes current detection methods and aims to catalyze the
development of next-generation analytical strategies.
Keywords: human growth hormone, sports doping, somatropin, performance
enhancement, World Anti-Doping Agency
